Poging GOUD - Vrij

Taiwan's Success Story In Combating Covid-19

BioSpectrum Asia

|

May 2020

COVID-19 has unravelled the potency and the feebleness of most geographical region’s healthcare, technical, social and political structure. While countries are anticipating various dimensions to tackle coronavirus and combat the pandemic, Taiwan’s success in controlling COVID-19 has bolstered its global standing despite the close geographical proximity with China. The resilient island aggregated its forces to tackle the virus and circumstances rationally with well-established pandemic control strategies, bio medical assets, advanced IoT capabilities, impeccable healthcare system and a well organised political force. Taiwan apparently grappled the coronavirus incredibly well and is now keen to offer medical and technical assistance to other countries in this global crisis.

- Hithaishi C Bhaskar 

Taiwan's Success Story In Combating Covid-19

Taiwan, an island state in East Asia is located at less than 150 km sea route away from China, the epicentre of COVID-19 outbreak. Among the 23 million population of the island 850 000 reside-in and 404 000 work in China. Though the world’s corona death tool is steeping with elevated graph, Taiwan has recorded only 429 cases and 6 reported deaths as of April 30, 2020.

Taiwan has always been provident from its earlier lessons learnt during SARS outbreak in 2003. Thus, the country became hyper-vigilant once the first case of mysterious pneumonia reported in Wuhan, China. Taiwan developed its proficient and self-established health system to address any upcoming pandemic or epidemic. Taiwan’s advanced hub is combating COVID-19 through science, technology, and democratic proactive governance and most importantly independent of WHO tracking system. Taiwan believes in strategic pre planning prior to the outbreak and constantly reviews immigration policies as and when the situation evolves to monitor any emerging infectious diseases.

Taiwan’ trajectories and execution strategies in assessing COVID-19 and quick actions in preventing a large-scale epidemic may be instructive for other countries as the virus continue to threaten global health and economies.

Rapid response and effective strategies

Ever since the SARS epidemic in 2003, Taiwan has been on constant alert by establishing public health response mechanism which activates emergency public health management structures. Taiwan proficient teams quickly mobilize and institute specific approaches for case identification, containment, and resource allocation.

MEER VERHALEN VAN BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Waters launches charge detection mass spectrometry technology

US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia

The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

WHO strengthens coordination for NTD programmes and supply chain delivery

The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

All-in-one coronavirus vaccines to save millions in future pandemics

A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

NTU in Singapore introduces Master of Science course in Chinese Medicine

From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

ProSpecBio launches Activin-A recombinant protein for brain injury research

Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

PAHO publishes guide for designing AI instructions in public health

The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Prerna launches India's first MicroRNA based blood test for breast cancer screening

Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr

India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan

Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.

time to read

1 min

BioSpectrum Asia Nov 2025

Translate

Share

-
+

Change font size